ADC Therapeutics
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 274
- Market Cap
- $295.7M
- Introduction
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Clinical Trials
49
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Loncastuximab Tesirine For Injection
- Product Name
- 泽路泰
- Approval Number
- 国药准字SJ20240046
- Approval Date
- Dec 6, 2024
Clinical Trials
Distribution across different clinical trial phases (47 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
- Conditions
- High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 56
- Registration Number
- NCT05660395
- Locations
- 🇺🇸
The Oncology Institute of Hope & Innovation - Lynwood, Lynwood, California, United States
🇧🇷Hospital Sírio-Libanês - Brasília, Brasília, Brazil
🇧🇷Hospital Mãe de Deus - Centro Integrado de Oncologia, Porto Alegre, Brazil
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 128
- Registration Number
- NCT05389462
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸Stanford Cancer Center, Stanford Medicine at Stanford University, Stanford, California, United States
🇺🇸University of IOWA, Iowa City, Iowa, United States
Long-term Registry of Patients Treated With Loncastuximab Tesirine
- Conditions
- B-Cell Lymphomas
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- ADC Therapeutics S.A.
- Registration Number
- NCT05160064
- Locations
- 🇺🇸
Compassionate Cancer Care Medical Group, Fountain Valley, California, United States
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 41
- Registration Number
- NCT05144009
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States
🇺🇸Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- ADC Therapeutics S.A.
- Registration Number
- NCT04974996
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
ADC Therapeutics Secures $100 Million Financing to Advance ZYNLONTA Development Through 2028
ADC Therapeutics raised $100 million through a private placement financing to extend its cash runway into 2028 and fund ZYNLONTA clinical development programs.
ADC Therapeutics Completes Enrollment in Phase 3 LOTIS-5 Trial for Zynlonta in Relapsed/Refractory DLBCL
ADC Therapeutics has completed enrollment for the LOTIS-5 Phase 3 trial evaluating Zynlonta plus rituximab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
ZYNLONTA® Plus Rituximab Demonstrates High Response Rates in Relapsed/Refractory Follicular Lymphoma
A Phase 2 trial of ZYNLONTA® with rituximab in relapsed/refractory follicular lymphoma showed a 97% overall response rate (ORR) and 77% complete response (CR) rate.
Loncastuximab Tesirine Shows Promise in Relapsed/Refractory Follicular and Marginal Zone Lymphomas
Loncastuximab tesirine with rituximab demonstrates a 97% overall response rate and a 67% complete response rate in relapsed/refractory follicular lymphoma patients.
ADC Therapeutics Announces Data Update from LOTIS-7 Trial of ZYNLONTA® Plus Glofitamab in R/R DLBCL
ADC Therapeutics will present initial data from the LOTIS-7 Phase 1b trial on December 11, 2024, evaluating ZYNLONTA® with glofitamab in relapsed/refractory DLBCL.
BerGenBio's AXL Inhibitor Receives FDA Fast Track for STK11-Mutated Cancers Amidst Leadership Transition
BerGenBio's AXL inhibitor receives FDA Fast Track designation, highlighting its potential in treating STK11-mutated cancers, addressing a significant unmet medical need.
ADC Therapeutics' Zynlonta Faces Competition, Poised for Potential Second-Line DLBCL Approval
ADC Therapeutics' Zynlonta (loncastuximab tesirine-Ipyl) is a CD19-directed antibody-drug conjugate approved for relapsed/refractory large B-cell lymphoma.
FDA Intensifies Scrutiny on Accelerated Approvals for Cancer Drugs, Mandating Earlier Confirmatory Trials
• The FDA is increasing its requirements for accelerated approvals of cancer drugs, emphasizing the need for companies to have comprehensive confirmatory trial plans upfront. • The Oncology Center of Excellence now wants to see confirmatory trials underway when companies submit applications for accelerated approvals, potentially impacting smaller biotechs. • FDA's policy aims to reduce the vulnerability period between accelerated approval and efficacy confirmation or market withdrawal, which has historically been lengthy when confirmatory trials are delayed. • The new stance reflects a shift towards ensuring patient benefit is the primary focus of accelerated approvals, rather than serving as an incentive program for the industry.